Tylophorine-based compounds exert broad spectral, potent inhibition of coronaviruses.NF-κB activation is a common pro-inflammatory response of host cells to viral infection.The combination treatment, wherein a tylophorine compound targets TGEV and a JAK2 inhibitor blocks the alternative dominant NF-κB activation mediated by JAK2, is more effective and comprehensive than either one alone and constitutes a feasible approach for the treatment of SARS-CoV or MERS-CoV. Here, NFKB1 is linked to viral infectious disease.